Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate
Portfolio Pulse from Vandana Singh
Silence Therapeutics announced positive results from the APOLLO phase 1 study of zerlasiran, showing significant reduction in lipoprotein(a) levels. The drug was well tolerated with no major safety concerns. HC Wainwright reiterated an $80 price target and Buy rating, predicting peak annual revenues of $2 billion for zerlasiran. SLN shares closed up 29.30% at $8.66 on Wednesday.
November 01, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics' zerlasiran shows promising results in phase 1 study, potentially boosting the company's revenues and stock price.
The positive results from the phase 1 study of zerlasiran, along with the positive outlook from HC Wainwright, are likely to increase investor confidence in Silence Therapeutics, potentially leading to a rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100